Novartis's Sandoz to Appeal Erelzi Patent Case in US
12 Agosto 2019 - 8:24AM
Dow Jones News
By Anthony Shevlin
Novartis AG's (NOVN.EB) generic-drug division Sandoz said late
Friday that it will appeal a District Court of New Jersey ruling in
a U.S. patent case concerning biosimilar Erelzi.
The Swiss pharma giant's Sandoz division said it will appeal the
decision to the U.S. Court of Appeals for the Federal Circuit, and
the parties have agreed to an expedited appeal.
"Sandoz respectfully disagrees with the court's ruling, which
prevents us from launching an additional treatment option for
patients with autoimmune and inflammatory diseases," said Carol
Lynch, president of Sandoz U.S. and head of North America.
"Amgen asserted two patents that it obtained from Roche Holding
AG (ROG.EB), in what we believe is an attempt to extend its U.S.
compound patent protection for etanercept to 2029," Ms. Lynch
said.
Sandoz said it remains committed to providing Erelzi as soon as
possible.
Write to Anthony Shevlin at anthony.shevlin@dowjones.com;
@anthony_shevlin
(END) Dow Jones Newswires
August 12, 2019 02:09 ET (06:09 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Novartis (NYSE:NVS)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Novartis (NYSE:NVS)
Storico
Da Apr 2023 a Apr 2024
